Clinical trials: Age Related Maculopathy
Macular Degeneration
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
A study evaluating Retisert in patients with age-related macular degeneration
- Trial name
- NCT00032396
- Testing
- Retisert Implant
- Where
- United States
- Sponsor
- Control Delivery Systems
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
- Trial name
- NCT00857259
- Testing
- Everolimus, Ranibizumab
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
ERG/EOG Study in AMD Patients Treated With Ranibizumab
This is an open-label study assessing electrophysiologic testing of the retina with Electoretinogram (ERG) /Electrooculogram (EOG) tests in patients with exudative age-related macular degeneration (AMD).
- Trial name
- FVF4154s (NCT00791427)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Retina Center, Minnesota
Age-related Macular Degeneration
Vision Improvement for Patients With Age-Related Macular Degeneration
The purpose of this study is to determine whether the Optimal Acuity Clear-K® Low Vision Aid System provides a safe and effective treatment to improve vision for patients with age-related macular degeneration.
- Trial name
- AMD (NCT04268836)
- Testing
- Optimal Acuity Clear-K® Low Vision Aid System treatment
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Age-related Macular Degeneration
Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration
The global aim of this project is to expand the knowledge on the multifactorial pathogenesis of AMD. In addition to age, the multifactorial pathogenesis of AMD includes environmental and genetic risk factors.
- Trial name
- AMDMetab (NCT04241536)
- Testing
- Blood draw and urine collection
- Where
- Portugal
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with…
- Trial name
- GALLEGO (NCT03972709)
- Testing
- Galegenimab
- Where
- 72 sites in United States
- Volunteers
- 372 people
- Sponsor
- Genentech, Inc.
Exudative Age Related Macular Degeneration
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus Standard of Care Anti-VEGF Monotherapy
- Trial name
- NCT04075136
- Testing
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Cataract Senile, Macula Hole
Ocular Coherence Tomography During Cataract Assessment
Many patients will have underlying maculopathy present when undergoing cataract surgery, which are not visible on fundoscopy alone.
- Conditions
- Cataract Senile, Macula Hole, Epiretinal Membrane, Age Related Macular Degeneration
- Trial name
- NCT05287269
- Testing
- Ocular Coherence Tomography
- Where
- United Kingdom
- Volunteers
- 626 people, healthy volunteers welcome
- Sponsor
- Brighton and Sussex University Hospitals NHS Trust
Neovascular Age-related Macular Degeneration
Development of an Optimal Algorithm for the Management of Patients With Retinal Pigment Epithelium Detachment in Neovascular Age-related Macular Degeneration Using Artificial Intelligence
The study involves the development of an algorithm for predicting anatomical and functional results of therapy with angiogenesis inhibitors in patients with retinal pigment epithelium detachments in neovascular age-related…
- Trial name
- NCT05208931
- Testing
- Anti-vascular endothelial growth factor therapy
- Where
- Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The S.N. Fyodorov Eye Microsurgery State Institution
Age-related Macular Degeneration (ARMD)
Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities
Age-related macular degeneration (AMD) is one of the main causes of blindness in the elderly population. Intraocular injection of anti-VEGF drugs for neovascular AMD (nAMD) is the main treatment method at present.
- Trial name
- NCT06583109
- Volunteers
- 2,600 people
- Sponsor
- Beijing Hospital
Dry Macular Degeneration, Geographic Atrophy
Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular…
- Trial name
- NCT02590692
- Testing
- CPCB-RPE1
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regenerative Patch Technologies, LLC
Macular Degeneration
Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (in Combination With Intravitreal Triamcinolone Acetate)
To assess the CNV treatment effect of PDT with verteporfin in combination with IVTA using reduced fluence compared to the standard fluence.
- Trial name
- NCT00523406
- Testing
- Photodynamic therapy and intravitreal triamcinolone
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Dry Age-related Macular Degeneration
QA102 Phase II Study in Subjects With Dry AMD
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA)…
- Trial name
- AMEND (NCT05536752)
- Testing
- QA102
- Where
- 29 sites in United States
- Volunteers
- 150 people
- Sponsor
- Smilebiotek Zhuhai Limited
Macular Degeneration
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety…
- Trial name
- NCT00460408
- Testing
- Macugen
- Where
- 68 sites in Belgium, Cyprus and 11 more
- Volunteers
- 501 people
- Sponsor
- Pfizer
AMD
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Currently, there is no safe way to obtain cells from the eye to study.
- Trial name
- NCT03372746
- Where
- 14 sites in United States
- Volunteers
- 187 people
- Sponsor
- National Eye Institute (NEI)
Dry Age-related Macular Degeneration
Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular…
- Trial name
- M-CORD IV (NCT06536062)
- Testing
- Intravitreal injection of CB-PRP
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal…
- Trial name
- NCT00284089
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 88 people
- Sponsor
- Novartis
Macular Degeneration
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD. The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap…
- Trial name
- NCT00320788
- Testing
- aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in United States
- Volunteers
- 159 people
- Sponsor
- Regeneron Pharmaceuticals
Geographic Atrophy
A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD).
- Trial name
- Proxima A (NCT02479386)
- Testing
- No intervention
- Where
- 91 sites in United States, Argentina and 13 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Age Related Macular Degeneration
Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic…
- Trial name
- MANTA (NCT00710229)
- Testing
- Ranibizumab, Bevacizumab
- Where
- Austria
- Volunteers
- 320 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.